PT - JOURNAL ARTICLE AU - Tue W. Kragstrup AU - Helene Søgaard Singh AU - Ida Grundberg AU - Ane Langkilde-Lauesen Nielsen AU - Felice Rivellese AU - Arnav Mehta AU - Marcia B. Goldberg AU - Michael Filbin AU - Per Qvist AU - Bo Martin Bibby TI - Plasma ACE2 levels predict outcome of COVID-19 in hospitalized patients AID - 10.1101/2021.03.08.21252819 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.08.21252819 4099 - http://medrxiv.org/content/early/2021/03/10/2021.03.08.21252819.short 4100 - http://medrxiv.org/content/early/2021/03/10/2021.03.08.21252819.full AB - Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin converting enzyme 2 (ACE2) enabling entrance of the virus into cells and causing the infection termed coronavirus disease of 2019 (COVID-19). COVID-19 is a disease with a very broad spectrum of clinical manifestations, ranging from asymptomatic and subclinical infection to severe hyperinflammatory syndrome and death.Methods This study used data from a large longitudinal study of 306 COVID-19 positive patients and 78 COVID-19 negative patients (MGH Emergency Department COVID-19 Cohort with Olink Proteomics). Comprehensive clinical data were collected on this cohort, including 28-day outcomes classified according to the World Health Organization (WHO) COVID-19 outcomes scale. The samples were run on the Olink® Explore 1536 platform which includes measurement of the ACE2 protein.Findings High baseline levels of ACE2 in plasma from COVID-19 patients were associated with worse WHOmax category at 28 days with OR=0.56, 95%-CI: 0.44-0.71 (P < 0.0001). This association was significant in regression models with correction for baseline characteristics, pre-existing medical conditions, and laboratory test results. High levels of ACE2 in plasma from COVID-19 patients were also significantly associated with worse WHO category at the time of blood sampling at both day 0, day 3, and day 7 (P = 0.0004, P < 0.0001, and P < 0.0001, respectively). The levels of ACE2 in plasma from COVID-19 patients with hypertension were significantly higher compared to patients without hypertension (P = 0.0045). The plasma ACE2 levels were also significantly higher in COVID-19 patients with pre-existing heart conditions and kidney disease compared with patients without these pre-existing conditions (P = 0.0363 and P = 0.0303, respectively). There was no difference in plasma ACE2 levels comparing patients with or without pre-existing lung disease, diabetes, or immunosuppressive conditions (P = 0.953, P = 0.291, and P = 0.237, respectively). The associations between high plasma levels of ACE2 and worse WHOmax category during 28 days were more pronounced in COVID-19 positive patients compared with COVID-19 negative patients but the difference was not significant in the two-way ANOVA analysis.This study suggests that measuring ACE2 is potentially valuable in predicting COVID-19 outcomes. Further, ACE2 levels could be a link between severe COVID-19 disease and its risk factors, namely hypertension, pre-existing heart disease and pre-existing kidney disease. The design of the data analysis using the Olink platform does not allow assessment of quantitative differences. However, previous studies have described a positive correlation between plasma ACE2 and ACE1 activity. This is interesting because ACE1 (serum ACE) analysis is a standardized test in most hospital laboratories. Therefore, our study encourages quantitative investigations of both plasma ACE 1 and 2 in COVID-19.Question Can plasma levels of the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), angiotensin converting enzyme 2 (ACE2), predict outcome of coronavirus disease of 2019 (COVID-19).Findings In this study of 306 COVID-19 positive patients, high baseline levels of ACE2 in plasma from COVID-19 patients were associated with worse outcome measured by the World Health Organization (WHO) COVID-19 outcomes scale.Meaning Measuring ACE2 is potentially valuable in predicting COVID-19 outcomes and link COVID-19 disease and the risk factors hypertension, pre-existing heart disease and pre-existing kidney disease.Competing Interest StatementIG is an employee of Olink Proteomics. The authors declare no other potential conflicts of interest.Funding StatementAmerican Lung Association COVID-19 Action Initiative award (MBG). Independent Research Fund Denmark clinician scientist award (9039-00015B, TWK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sample collection and analysis was approved by Partners Human Research Committee (PHRC).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is publicly available. https://www.olink.com/mgh-covid-study/ ACEAngiotensin converting enzymeAng IAngiotensin IAng IIAngiotensin IIANOVAAnalysis of varianceAT1RType 1 angiotensin II receptorAUCArea under the curveBMIBody mass indexCoVCoronavirusCOVID-19Corona virusdisease 2019 CRPC-reactive proteinILInterleukinNPXNormalized Protein eXpressionPEAProximity extension assayRAASRenin-angiotensin-aldosterone-systemROCreceiver operating characteristicSARS-CoV-2Severe acute respiratory syndrome coronavirus 2TNFTumor necrosis factor